Top

Published in:

01-11-2008 | ssat poster presentation

Fluorophore-conjugated anti-CEA Antibody for the Intraoperative Imaging of Pancreatic and Colorectal Cancer

Authors: Sharmeela Kaushal, Michele K. McElroy, George A. Luiken, Mark A. Talamini, A. R. Moossa, Robert M. Hoffman, Michael Bouvet

Published in: Journal of Gastrointestinal Surgery | Issue 11/2008

Abstract

Introduction

Colorectal and pancreatic cancers together comprise the third and fourth most common causes of cancer-related death in the United States. In both of these cancers, complete detection of primary and metastatic lesions at the time of surgery is critical to optimal surgical resection and appropriate patient treatment.

Materials and Methods

We have investigated the use of fluorophore-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody to aid in cancer visualization in nude mouse models of human colorectal and pancreatic cancer. Anti-CEA was conjugated with a green fluorophore. Subcutaneous, orthotopic primary and metastatic human pancreatic and colorectal tumors were easily visualized with fluorescence imaging after administration of conjugated anti-CEA. The fluorescence signal was detectable 30 min after systemic antibody delivery and remained present for 2 weeks, with minimal in vivo photobleaching after exposure to standard operating room lighting. Tumor resection techniques revealed improved ability to resect labeled tumor tissue under fluorescence guidance. Comparison of two different fluorophores revealed differences in dose–response and photobleaching in vivo.

Conclusion

These results indicate that fluorophore-labeled anti-CEA offers a novel intraoperative imaging technique for enhanced visualization of tumors in colorectal and pancreatic cancer when CEA expression is present, and that the choice of fluorophore significantly affects the signal intensity in the labeled tumor.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30.PubMed

Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005;128:1626–41. doi:10.1053/j.gastro.2005.03.035.PubMedCrossRef

Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM et al. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007;110:525–33. doi:10.1002/cncr.22809.PubMedCrossRef

Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology 2007;72:314–21. doi:10.1159/000113054.PubMedCrossRef

Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–94. doi:10.1002/bjs.4484.PubMedCrossRef

Robinson MH, Thomas WM, Hardcastle JD, Chamberlain J, Mangham CM. Change towards earlier stage at presentation of colorectal cancer. Br J Surg 1993;80:1610–2. doi:10.1002/bjs.1800801241.PubMedCrossRef

Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008;13:51–64. doi:10.1634/theoncologist.2007-0142.PubMedCrossRef

Bonjer HJ, Hop WC, Nelson H, Sargent DJ, Lacy AM, Castells A et al. Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg 2007;142:298–303. doi:10.1001/archsurg.142.3.298.PubMedCrossRef

Turrini O, Viret F, Guiramand J, Lelong B, Bege T, Delpero JR. Strategies for the treatment of synchronous liver metastasis. Eur J Surg Oncol 2007;33:735–40. doi:10.1016/j.ejso.2007.02.025.PubMed

10.

Andreoni B, Chiappa A, Bertani E, Bellomi M, Orecchia R, Zampino M et al. Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World J Surg Oncol 2007;5:73. doi:10.1186/1477-7819-5-73.PubMedCrossRef

11.

Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439–62. doi:10.1084/jem.121.3.439.PubMedCrossRef

12.

Gold P, Shuster J, Freedman SO. Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer 1978;42:1399–405. doi:10.1002/1097-0142(197809)42:3+<1399::AID-CNCR2820420803>3.0.CO;2-P.PubMedCrossRef

13.

Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467–81. doi:10.1084/jem.122.3.467.PubMedCrossRef

14.

Albers GH, Fleuren G, Escribano MJ, Nap M. Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma. Am J Clin Pathol 1988;90:17–22.PubMed

15.

Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991;47:148–54. doi:10.1002/jso.2930470303.PubMedCrossRef

16.

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313–27. doi:10.1200/JCO.2006.08.2644.PubMedCrossRef

17.

Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23:338–51.PubMed

18.

Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 1991;88:9345–9. doi:10.1073/pnas.88.20.9345.PubMedCrossRef

19.

Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H et al. Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res 2006;66:4208–14. doi:10.1158/0008-5472.CAN-05-3927.PubMedCrossRef

20.

Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349–56. doi:10.1038/nrd2241.PubMedCrossRef

21.

Suzuki K, Kodama N, Sasaki T, Matsumoto M, Ichikawa T, Munakata R et al. Confirmation of blood flow in perforating arteries using fluorescein cerebral angiography during aneurysm surgery. J Neurosurg 2007;107:68–73. doi:10.3171/JNS-07/07/0068.PubMedCrossRef

22.

Bartlett H, Eperjesi F. use of fundus imaging in quantification of age-related macular change. Surv Ophthalmol 2007;52:655–71. doi:10.1016/j.survophthal.2007.08.022.PubMedCrossRef

23.

Hama Y, Urano Y, Koyama Y, Bernardo M, Choyke PL, Kobayashi H. A comparison of the emission efficiency of four common green fluorescence dyes after internalization into cancer cells. Bioconjug Chem 2006;17:1426–31. doi:10.1021/bc0601626.PubMedCrossRef

24.

Itzkowitz SH, Shi ZR, Kim YS. Heterogeneous expression of two oncodevelopmental antigens, CEA and SSEA-1, in colorectal cancer. Histochem J 1986;18:155–63. doi:10.1007/BF01676115.PubMedCrossRef

25.

Pihl E, McNaughtan J, Ward HA, Nairn RC. Immunohistological patterns of carcinoembryonic antigen in colorectal carcinoma. Correlation with staging and blood levels. Pathology 1980;12:7–13. doi:10.3109/00313028009060048.PubMedCrossRef

26.

Tsavellas G, Patel H, Allen-Mersh TG. Detection and clinical significance of occult tumour cells in colorectal cancer. Br J Surg 2001;88:1307–20. doi:10.1046/j.0007-1323.2001.01863.x.PubMedCrossRef

27.

Kim JC, Gong G, Roh SA, Park KC. Carcinoembryonic antigen gene and carcinoembryonic antigen expression in the liver metastasis of colorectal carcinoma. Mol Cells 1999;9:133–7.PubMed

28.

Prall F, Nollau P, Neumaier M, Haubeck HD, Drzeniek Z, Helmchen U et al. CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. J Histochem Cytochem 1996;44:35–41.PubMed

29.

Nap M, Mollgard K, Burtin P, Fleuren GJ. Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 1988;9:145–53.PubMedCrossRef

30.

Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67–81. doi:10.1006/scbi.1998.0119.PubMedCrossRef

31.

Song L, Hennink EJ, Young IT, Tanke HJ. Photobleaching kinetics of fluorescein in quantitative fluorescence microscopy. Biophys J 1995;68:2588–600.PubMed

32.

Hama Y, Urano Y, Koyama Y, Choyke PL, Kobayashi H. Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res 2007;67:3809–17. doi:10.1158/0008-5472.CAN-06-3794.PubMedCrossRef

33.

Withrow KP, Newman JR, Skipper JB, Gleysteen JP, Magnuson JS, Zinn K et al. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts. Technol Cancer Res Treat 2008;7:61–6.PubMed

34.

Kulbersh BD, Duncan RD, Magnuson JS, Skipper JB, Zinn K, Rosenthal EL. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg 2007;133:511–5. doi:10.1001/archotol.133.5.511.PubMedCrossRef

35.

Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res 2007;13:2936–45. doi:10.1158/1078-0432.CCR-06-2240.PubMedCrossRef

36.

McElroy M, Kaushal S, Luiken GA, Talamini MA, Moossa AR, Hoffman RM, Bouvet M. Imaging of primary and metastatic pancreatic cancer using a fluorophore–conjugated anti-CA19-9 antibody for surgical navigation. World J Surg 2008;32:1057–1066.PubMedCrossRef

37.

Yang M, Luiken G, Baranov E, Hoffman RM. Facile whole-body imaging of internal fluorescent tumors in mice with an LED flashlight. Biotechniques 2005;39:170–172.PubMedCrossRef

38.

Zopf T, Schneider AR, Weickert U, Riemann JF, Arnold JC. Improved preoperative tumor staging by 5-aminolevulinic acid induced fluorescence laparoscopy. Gastrointest Endosc 2005;62:763–7. doi:10.1016/j.gie.2005.05.020.PubMedCrossRef

Title: Fluorophore-conjugated anti-CEA Antibody for the Intraoperative Imaging of Pancreatic and Colorectal Cancer
Authors: Sharmeela Kaushal
Michele K. McElroy
George A. Luiken
Mark A. Talamini
A. R. Moossa
Robert M. Hoffman
Michael Bouvet
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 11/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-008-0581-0

At a glance: The STEP trials

Springer Medicine

Fluorophore-conjugated anti-CEA Antibody for the Intraoperative Imaging of Pancreatic and Colorectal Cancer

Abstract

Introduction

Materials and Methods

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Materials and Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2008

Gastrectomy and Lymphadenectomy for Gastric Cancer: is the Pancreas Safe?

Monopolar Floating Ball Versus Bipolar Forceps for Hepatic Resection: A Prospective Randomized Clinical Trial

Laparoscopic-assisted vs. Open Colectomy for Cancer: Comparison of Short-term Outcomes from 121 Hospitals

Surgical Outcomes of Patients with Gastrointestinal Stromal Tumors in the Era of Targeted Drug Therapy

Resection Versus Laparoscopic Radiofrequency Thermal Ablation Of Solitary Colorectal Liver Metastasis

Surgical Management of Failed Endoscopic Treatment of Pancreatic Disease